New antiarrhythmic treatment of atrial fibrillation

Gerald Naccarelli, Deborah Wolbrette, Soraya Samii, Javier E. Banchs, Erica Penny-Peterson, Mario Gonzalez

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Antiarrhythmic pharmaceutical development for the treatment of atrial fibrillation (AF) is moving in several directions. The efficacy of existing drugs, such as carvedilol, for rate control and, possibly, suppression of AF, is more appreciated. Efforts are being made to modify existing agents, such as amiodarone, in an attempt to amellorate safety and adverse effect concerns. This has resulted in promising data from the delodinated amlodarone analog, dronedarone, and further work with cellvarone and ATI-2042. In an attempt to minimize ventricular proarrhythmia, atrial selective drugs, such as intravenous vernakalant, have demonstrated efficacy in terminating AF in addition to promising data in suppression recurrences when used orally. Several other atrial selective drugs are being developed by multiple manufacturers. Other novel therapeutic mechanisms, such as drugs that enhance GAP junction conduction, are being developed to achieve more effective drug therapy than is offered by existing compounds. Finally, nonantiarrhythmic drugs, such as angiotensin-converting enzyme inhibitors, anglotensin receptor blockers, high-mobility group coenzyme A enzyme inhibitors and omega-3 fatty acids/fish oil, appear to have a role in suppressing AF in certain patient subtypes. Future studies will clarify the role of these drugs in treating AF.

Original languageEnglish (US)
Pages (from-to)707-714
Number of pages8
JournalExpert Review of Cardiovascular Therapy
Volume5
Issue number4
DOIs
StatePublished - Jul 1 2007

Fingerprint

Atrial Fibrillation
Pharmaceutical Preparations
Therapeutics
Amiodarone
Fish Oils
Anti-Arrhythmia Agents
Omega-3 Fatty Acids
Enzyme Inhibitors
Coenzyme A
Angiotensin-Converting Enzyme Inhibitors
Safety
Recurrence
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{7fe2f2b6f8c54dfa908eedf31d92a6f5,
title = "New antiarrhythmic treatment of atrial fibrillation",
abstract = "Antiarrhythmic pharmaceutical development for the treatment of atrial fibrillation (AF) is moving in several directions. The efficacy of existing drugs, such as carvedilol, for rate control and, possibly, suppression of AF, is more appreciated. Efforts are being made to modify existing agents, such as amiodarone, in an attempt to amellorate safety and adverse effect concerns. This has resulted in promising data from the delodinated amlodarone analog, dronedarone, and further work with cellvarone and ATI-2042. In an attempt to minimize ventricular proarrhythmia, atrial selective drugs, such as intravenous vernakalant, have demonstrated efficacy in terminating AF in addition to promising data in suppression recurrences when used orally. Several other atrial selective drugs are being developed by multiple manufacturers. Other novel therapeutic mechanisms, such as drugs that enhance GAP junction conduction, are being developed to achieve more effective drug therapy than is offered by existing compounds. Finally, nonantiarrhythmic drugs, such as angiotensin-converting enzyme inhibitors, anglotensin receptor blockers, high-mobility group coenzyme A enzyme inhibitors and omega-3 fatty acids/fish oil, appear to have a role in suppressing AF in certain patient subtypes. Future studies will clarify the role of these drugs in treating AF.",
author = "Gerald Naccarelli and Deborah Wolbrette and Soraya Samii and Banchs, {Javier E.} and Erica Penny-Peterson and Mario Gonzalez",
year = "2007",
month = "7",
day = "1",
doi = "10.1586/14779072.5.4.707",
language = "English (US)",
volume = "5",
pages = "707--714",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "4",

}

New antiarrhythmic treatment of atrial fibrillation. / Naccarelli, Gerald; Wolbrette, Deborah; Samii, Soraya; Banchs, Javier E.; Penny-Peterson, Erica; Gonzalez, Mario.

In: Expert Review of Cardiovascular Therapy, Vol. 5, No. 4, 01.07.2007, p. 707-714.

Research output: Contribution to journalReview article

TY - JOUR

T1 - New antiarrhythmic treatment of atrial fibrillation

AU - Naccarelli, Gerald

AU - Wolbrette, Deborah

AU - Samii, Soraya

AU - Banchs, Javier E.

AU - Penny-Peterson, Erica

AU - Gonzalez, Mario

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Antiarrhythmic pharmaceutical development for the treatment of atrial fibrillation (AF) is moving in several directions. The efficacy of existing drugs, such as carvedilol, for rate control and, possibly, suppression of AF, is more appreciated. Efforts are being made to modify existing agents, such as amiodarone, in an attempt to amellorate safety and adverse effect concerns. This has resulted in promising data from the delodinated amlodarone analog, dronedarone, and further work with cellvarone and ATI-2042. In an attempt to minimize ventricular proarrhythmia, atrial selective drugs, such as intravenous vernakalant, have demonstrated efficacy in terminating AF in addition to promising data in suppression recurrences when used orally. Several other atrial selective drugs are being developed by multiple manufacturers. Other novel therapeutic mechanisms, such as drugs that enhance GAP junction conduction, are being developed to achieve more effective drug therapy than is offered by existing compounds. Finally, nonantiarrhythmic drugs, such as angiotensin-converting enzyme inhibitors, anglotensin receptor blockers, high-mobility group coenzyme A enzyme inhibitors and omega-3 fatty acids/fish oil, appear to have a role in suppressing AF in certain patient subtypes. Future studies will clarify the role of these drugs in treating AF.

AB - Antiarrhythmic pharmaceutical development for the treatment of atrial fibrillation (AF) is moving in several directions. The efficacy of existing drugs, such as carvedilol, for rate control and, possibly, suppression of AF, is more appreciated. Efforts are being made to modify existing agents, such as amiodarone, in an attempt to amellorate safety and adverse effect concerns. This has resulted in promising data from the delodinated amlodarone analog, dronedarone, and further work with cellvarone and ATI-2042. In an attempt to minimize ventricular proarrhythmia, atrial selective drugs, such as intravenous vernakalant, have demonstrated efficacy in terminating AF in addition to promising data in suppression recurrences when used orally. Several other atrial selective drugs are being developed by multiple manufacturers. Other novel therapeutic mechanisms, such as drugs that enhance GAP junction conduction, are being developed to achieve more effective drug therapy than is offered by existing compounds. Finally, nonantiarrhythmic drugs, such as angiotensin-converting enzyme inhibitors, anglotensin receptor blockers, high-mobility group coenzyme A enzyme inhibitors and omega-3 fatty acids/fish oil, appear to have a role in suppressing AF in certain patient subtypes. Future studies will clarify the role of these drugs in treating AF.

UR - http://www.scopus.com/inward/record.url?scp=34447328696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447328696&partnerID=8YFLogxK

U2 - 10.1586/14779072.5.4.707

DO - 10.1586/14779072.5.4.707

M3 - Review article

C2 - 17605649

AN - SCOPUS:34447328696

VL - 5

SP - 707

EP - 714

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 4

ER -